MedTrace Logo

Pregabalin Phonophoresis for Carpal Tunnel Syndrome Pain

NCT07613476 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-29

No results posted yet for this study

Summary

Carpal tunnel syndrome (CTS) is a common condition caused by pressure on the median nerve in the wrist, leading to pain, numbness, and weakness in the hand. Oral medications for nerve pain can have significant side effects. This study tests a new, non-invasive approach. Pregabalin, a medication for neuropathic pain, will be mixed into a gel and delivered through the skin using therapeutic ultrasound, a method called phonophoresis. This avoids the digestive system and may reduce side effects. This randomized controlled trial will compare the effects of pregabalin phonophoresis against standard ultrasound therapy (without the drug) in 57 patients aged 20-40 with mild to moderate CTS. Treatments will occur 4 times per week for one month. Pain will be measured using the Numeric Pain Rating Scale, and hand function using the Boston Carpal Tunnel Questionnaire. The study aims to determine if pregabalin phonophoresis provides superior pain relief and functional improvement compared to ultrasound alone, offering a new, safe, and cost-effective physiotherapy treatment for CTS.

Conditions

  • Carpal Tunnel Syndrome (CTS)

Interventions

OTHER

Pregabalin Phonophoresis

A topical gel containing pregabalin is applied to the volar aspect of the wrist over the carpal tunnel. A therapeutic ultrasound head (1 MHz, 1.5 W/cm²) is then moved in a circular motion over the gel for a total of 5 minutes per session. The ultrasound facilitates the transdermal delivery of pregabalin. This is administered 4 times per week for 4 weeks.

DEVICE

Therapeutic Ultrasound

Standard ultrasonic coupling gel is applied to the volar aspect of the wrist over the carpal tunnel. A therapeutic ultrasound head (1 MHz, 1.5 W/cm²) is then moved in a circular motion over the gel for a total of 5 minutes per session. This is administered 4 times per week for 4 weeks.

Sponsors & Collaborators

  • University of Faisalabad

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-07-19
Completion
2026-07-19

Countries

  • Pakistan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613476 on ClinicalTrials.gov